ARROWHEAD PHARMACEUTICALS, INC. Proceeds from Sale and Maturity of Marketable Securities
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Proceeds from Sale and Maturity of Marketable Securities of $34.43 million for the 3-month period ending 2020-12-31, per its 10-Q filed 2021-02-04.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2021-02-04
- ARROWHEAD PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2020-12-31 was $34.43M, a 153.15% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2020-06-30 was $9.55M, a 45.83% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2020-03-31 was $6.00M, a 39.89% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2019-12-31 was $13.60M, a 503.85% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2019 was $54.52M, a 18.35% increase from fiscal 2018.
- ARROWHEAD PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2018 was $46.07M, a 984.31% increase from fiscal 2017.
- ARROWHEAD PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2017 was $4.25M, a 75.45% decline from fiscal 2016.
- ARROWHEAD PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2016 was $17.31M, a 33.66% decline from fiscal 2015.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month | Proceeds from Sale and Maturity of Marketable Securities 98 month | Proceeds from Sale and Maturity of Marketable Securities 101 month | Proceeds from Sale and Maturity of Marketable Securities 104 month | Proceeds from Sale and Maturity of Marketable Securities 107 month | Proceeds from Sale and Maturity of Marketable Securities 110 month | Proceeds from Sale and Maturity of Marketable Securities 113 month | Proceeds from Sale and Maturity of Marketable Securities 116 month | Proceeds from Sale and Maturity of Marketable Securities 119 month | Proceeds from Sale and Maturity of Marketable Securities 122 month | Proceeds from Sale and Maturity of Marketable Securities 125 month | Proceeds from Sale and Maturity of Marketable Securities 128 month | Proceeds from Sale and Maturity of Marketable Securities 131 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | $34.43M 10-Q · filed 2021-02-04 | |||||||||||||||
| 2020-06-30 | $9.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-05 | $15.55M derived: sum of 2 quarters · filed 2020-08-05 | $29.15M 10-Q · filed 2020-08-05 | $53.81M derived: sum of 4 quarters · filed 2021-02-04 | ||||||||||||
| 2020-03-31 | $6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-07 | $19.60M 10-Q · filed 2020-05-07 | $44.26M derived: sum of 3 quarters · filed 2021-02-04 | $61.88M derived: sum of 4 quarters · filed 2021-02-04 | ||||||||||||
| 2019-12-31 | $13.60M 10-Q · filed 2021-02-04 | $38.26M derived: sum of 2 quarters · filed 2021-02-04 | $55.88M derived: sum of 3 quarters · filed 2021-02-04 | $65.87M derived: sum of 4 quarters · filed 2021-02-04 | ||||||||||||
| 2019-09-30 | $24.66M derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-25 | $42.28M derived: sum of 2 quarters · filed 2020-08-05 | $52.27M derived: sum of 3 quarters · filed 2020-08-05 | $54.52M 10-K · filed 2019-11-25 | ||||||||||||
| 2019-06-30 | $17.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-05 | $27.61M derived: sum of 2 quarters · filed 2020-08-05 | $29.86M 10-Q · filed 2020-08-05 | $38.73M derived: sum of 4 quarters · filed 2020-08-05 | ||||||||||||
| 2019-03-31 | $9.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-07 | $12.24M 10-Q · filed 2020-05-07 | $21.10M derived: sum of 3 quarters · filed 2020-05-07 | $34.60M derived: sum of 4 quarters · filed 2020-05-07 | ||||||||||||
| 2018-12-31 | $2.25M 10-Q · filed 2020-02-05 | $11.12M derived: sum of 2 quarters · filed 2020-02-05 | $24.62M derived: sum of 3 quarters · filed 2020-02-05 | $41.81M derived: sum of 4 quarters · filed 2020-02-05 | ||||||||||||
| 2018-09-30 | $8.87M derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-25 | $22.36M derived: sum of 2 quarters · filed 2019-11-25 | $39.56M derived: sum of 3 quarters · filed 2019-11-25 | $46.07M 10-K · filed 2019-11-25 | ||||||||||||
| 2018-06-30 | $13.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-05 | $30.69M derived: sum of 2 quarters · filed 2019-08-05 | $37.20M 10-Q · filed 2019-08-05 | $38.16M derived: sum of 4 quarters · filed 2019-11-25 | ||||||||||||
| 2018-03-31 | $17.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-08 | $23.70M 10-Q · filed 2019-05-08 | $24.66M derived: sum of 3 quarters · filed 2019-11-25 | |||||||||||||
| 2017-12-31 | $6.51M 10-Q · filed 2019-02-07 | $7.47M derived: sum of 2 quarters · filed 2019-11-25 | ||||||||||||||
| 2017-09-30 | $958.75K derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-25 | $4.25M 10-K · filed 2019-11-25 | ||||||||||||||
| 2017-06-30 | $3.29M 10-Q · filed 2018-08-07 | |||||||||||||||
| 2016-09-30 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-11 | $11.11M derived: sum of 2 quarters · filed 2018-12-11 | $14.31M derived: sum of 3 quarters · filed 2018-12-11 | $17.31M 10-K · filed 2018-12-11 | ||||||||||||
| 2016-06-30 | $10.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-08-03 | $13.31M derived: sum of 2 quarters · filed 2017-08-03 | $16.31M 10-Q · filed 2017-08-03 | $22.99M derived: sum of 4 quarters · filed 2017-12-12 | ||||||||||||
| 2016-03-31 | $3.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-05-03 | $6.20M 10-Q · filed 2017-05-03 | $12.88M derived: sum of 3 quarters · filed 2017-12-12 | $20.14M derived: sum of 4 quarters · filed 2017-12-12 | ||||||||||||
| 2015-12-31 | $3.00M 10-Q · filed 2017-02-06 | $9.68M derived: sum of 2 quarters · filed 2017-12-12 | $16.94M derived: sum of 3 quarters · filed 2017-12-12 | $26.04M derived: sum of 4 quarters · filed 2017-12-12 | ||||||||||||
| 2015-09-30 | $6.68M derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-12 | $13.94M derived: sum of 2 quarters · filed 2017-12-12 | $23.04M derived: sum of 3 quarters · filed 2017-12-12 | $26.09M 10-K · filed 2017-12-12 | ||||||||||||
| 2015-06-30 | $7.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-09 | $16.36M derived: sum of 2 quarters · filed 2016-08-09 | $19.41M 10-Q · filed 2016-08-09 | $24.41M derived: sum of 4 quarters · filed 2016-12-14 | ||||||||||||
| 2015-03-31 | $9.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-05-10 | $12.15M 10-Q · filed 2016-05-10 | $17.15M derived: sum of 3 quarters · filed 2016-12-14 | $18.73M derived: sum of 4 quarters · filed 2016-12-14 | ||||||||||||
| 2014-12-31 | $3.05M 10-Q · filed 2016-02-09 | $8.06M derived: sum of 2 quarters · filed 2016-12-14 | $9.64M derived: sum of 3 quarters · filed 2016-12-14 | $10.60M derived: sum of 4 quarters · filed 2016-12-14 | ||||||||||||
| 2014-09-30 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-14 | $6.58M derived: sum of 2 quarters · filed 2016-12-14 | $7.55M derived: sum of 3 quarters · filed 2016-12-14 | $11.59M 10-K · filed 2016-12-14 | ||||||||||||
| 2014-06-30 | $1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-08-04 | $2.54M derived: sum of 2 quarters · filed 2015-08-04 | $6.59M 10-Q · filed 2015-08-04 | $6.85M derived: sum of 4 quarters · filed 2015-12-14 | ||||||||||||
| 2014-03-31 | $964.28K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-05-11 | $5.01M 10-Q · filed 2015-05-11 | $5.27M derived: sum of 3 quarters · filed 2015-12-14 | $23.90M 10-Q · filed 2014-05-06 | ||||||||||||
| 2013-12-31 | $4.05M 10-Q · filed 2015-02-09 | $4.30M derived: sum of 2 quarters · filed 2015-12-14 | $22.93M 10-Q · filed 2014-02-04 | |||||||||||||
| 2013-09-30 | $258.90K derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-14 | $1.42M 10-K · filed 2015-12-14 | $18.89M 10-K · filed 2013-12-18 | |||||||||||||
| 2013-06-30 | $1.16M 10-Q · filed 2014-08-12 | $20.05M 10-Q · filed 2013-08-07 | ||||||||||||||
| 2013-03-31 | $18.89M 10-Q · filed 2013-05-09 | |||||||||||||||
| 2012-12-31 | $18.89M 10-Q · filed 2013-02-13 | |||||||||||||||
| 2012-09-30 | $509.01K 10-K · filed 2014-11-25 | $18.89M 10-K · filed 2012-12-28 | ||||||||||||||
| 2012-06-30 | $18.89M 10-Q · filed 2012-08-13 | |||||||||||||||
| 2012-03-31 | $18.89M 10-Q · filed 2012-05-08 | |||||||||||||||
| 2011-12-31 | $18.89M 10-Q · filed 2012-02-09 | |||||||||||||||
| 2011-09-30 | $18.89M 10-Q · filed 2012-08-13 | |||||||||||||||
| 2011-06-30 | $18.89M 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |